Market Research Logo

Global Myelofibrosis Therapeutics Market 2018-2022

Global Myelofibrosis Therapeutics Market 2018-2022

About this market

Myelofibrosis is as Philadelphia chromosome- negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/ JAK2 inhibitor used for treating the patients with myelofibrosis. HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis. Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease. Technavio’s analysts have predicted that the myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Market Overview

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies including the orphan drugs for this disorder is very limited. The treatment options employed by physicians are mostly the off- label drugs that are meant for the treatment of some other condition or the blood transfusion or stem cell transplantation.

For the detailed list of factors that will drive and challenge the growth of the myelofibrosis therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The global myelofibrosis therapeutics market is extremely concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Myelofibrosis Therapeutics Market 2018-2022

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the high off- label prescription including hydroxyurea, Immunomodulators and steroids.”

According to the report, one of the major drivers for this market is the increasing number of companies entering the myelofibrosis segment.

Further, the report states that one of the major factors hindering the growth of this market is the undefined etiology and unidentified cause of disease progression.

Companies Mentioned

Bristol-Myers Squibb
CELGENE
Incyte
Novartis

  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Pipeline analysis
    • Table Pipeline molecules for myelofibrosis 2017-2018
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global - Market size and forecast 2017-2022 ($ mn)
      • Table Global - Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Market segmentation by type of treatment
    • Segmentation by type of treatment
      • Table Type of treatment - Market share 2017-2022 (%)
    • Comparison by type of treatment
      • Table Comparison by type of treatment
    • Drug therapy - Market size and forecast 2017- 2022
      • Table Drug therapy - Market size and forecast 2017-2022 ($ mn)
      • Table JAKAVI/JAKAFI sales from 2015-2017
      • Table Drug therapy - Year-over-year growth 2018-2022 (%)
    • Blood transfusion - Market size and forecast 2017-2022
      • Table Blood transfusion - Market size and forecast 2017-2022 ($ mn)
      • Table Blood transfusion - Year-over-year growth 2018-2022 (%)
    • HSCT - Market size and forecast 2017-2022
      • Table HSCT - Market size and forecast 2017-2022 ($ mn)
      • Table HSCT - Year-over-year growth 2018-2022 (%)
    • Androgen Therapy - Market size and forecast 2017-2022
      • Table Androgen therapy - Market size and forecast 2017-2022 ($ mn)
      • Table Androgen Therapy - Year-over-year growth 2018-2022 (%)
    • Market opportunity by type of treatment
      • Table Market opportunity by type of treatment
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global - Market share by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Americas - Market size and forecast 2017-2022
      • Table Americas - Market size and forecast 2017-2022 ($ mn)
      • Table Americas - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in Americas
    • EMEA - Market size and forecast 2017-2022
      • Table EMEA - Market size and forecast 2017-2022 ($ mn)
      • Table EMEA - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in EMEA
    • APAC - Market size and forecast 2017-2022
      • Table APAC - Market size and forecast 2017-2022 ($ mn)
      • Table APAC - Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • HSCT is the only curative option for myelofibrosis
    • High off-label prescription including hydroxyurea, Immunomodulators, and steroids
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb - Overview
      • Table Bristol-Myers Squibb - Business segments
      • Table Bristol-Myers Squibb - Organizational developments
      • Table Bristol-Myers Squibb - Geographic focus
      • Table Bristol-Myers Squibb - Key offerings
      • Table Bristol-Myers Squibb - Key customers
    • CELGENE
      • Table CELGENE - Overview
      • Table CELGENE - Business segments
      • Table CELGENE - Organizational developments
      • Table CELGENE - Geographic focus
      • Table CELGENE - Key offerings
      • Table CELGENE - Key customers
    • Incyte
      • Table Incyte - Overview
      • Table Incyte - Business segments
      • Table Incyte - Organizational developments
      • Table Incyte - Geographic focus
      • Table Incyte - Key offerings
      • Table Incyte - Key customers
    • Novartis
      • Table Novartis - Overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
      • Table Novartis - Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report